On September 4, 2017, Orthocell Limited, which is a regenerative medicine company, announced that it had recruited and treated its first patient in a randomized and controlled clinical trial of its Ortho-ATI versus corticosteroid injection. The Ortho-ATI is designed for the treatment of rotator cuff tendinopathy and tear in the shoulder.
This injury is often difficult to treat and it impacts roughly 50% of adults over the age of 50. Depending on the severity of the injury, it can lead to considerable disability, work absences, and lowered quality of life. This condition can also be a burden on healthcare resources. As the population continues to age, it is anticipated that the burden will continue to compound.
The purpose of the trial is to determine the overall effectiveness of Autologous Tenocyte Injection, Ortho-ATI, compared to conventional corticosteroid injections. In order to be eligible for the clinical trials, patients must have failed previous conservative treatments.
The trial is being led by Clinical Professor Allan Wang, Bill Breidahl and Ming Hao Zheng. Studies to date suggest that Ortho-ATI may be a cost-effective long-term and durable, non-surgical solution for difficult to treat tendon injuries. At this point in time, Ortho-ATI is available in Australia, New Zealand, and Hong Kong with regulatory oversight.